Supplementary Tables | Volume 26 Number 2 | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table S1. Stage of disease at HIV diagnosis during 2017 among persons aged ≥13 years, by race/ethnicity and selected characteristics—41 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	121	11	9.1	35	28.9	33	27.3	23	19.0	19	15.7
Female	35	1	2.9	9	25.7	10	28.6	8	22.9	7	20.0
Transgender male-to-female^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Transgender female-to-male^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	20	2	10.0	9	45.0	5	25.0	1	5.0	3	15.0
25–34	64	6	9.4	24	37.5	19	29.7	7	10.9	8	12.5
35–44	33	2	6.1	5	15.2	12	36.4	7	21.2	7	21.2
45–54	28	2	7.1	6	21.4	5	17.9	13	46.4	2	7.1
≥55	11	0	0.0	0	0.0	2	18.2	3	27.3	6	54.5
Transmission category^e
Male-to-male sexual contact	88	7	8.0	29	33.6	25	28.9	15	17.6	10	11.9
Injection drug use
Male	9	2	21.3	1	10.6	1	13.8	3	35.1	2	19.1
Female	12	0	0.0	3	28.0	3	24.6	2	17.8	4	29.7
Male-to-male sexual contact and injection drug use	18	1	5.6	4	24.9	4	23.7	4	23.7	4	22.0
Heterosexual contact^f
Male	6	1	15.9	0	3.2	2	33.3	0	1.6	3	46.0
Female	23	1	4.3	6	24.6	7	30.6	6	25.4	4	15.1
Total^g	156	12	7.7	44	28.2	43	27.6	31	19.9	26	16.7
Asian
Gender
Male	724	35	4.8	137	18.9	272	37.6	179	24.7	101	14.0
Female	100	1	1.0	20	20.0	29	29.0	29	29.0	21	21.0
Transgender male-to-female^c	16	0	0.0	3	18.8	9	56.3	3	18.8	1	6.3
Transgender female-to-male^c	2	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0
Additional gender identity^d	1	1	100	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	175	12	6.9	34	19.4	83	47.4	17	9.7	29	16.6
25–34	274	15	5.5	50	18.2	110	40.1	62	22.6	37	13.5
35–44	200	5	2.5	45	22.5	67	33.5	49	24.5	34	17.0
45–54	134	6	4.5	24	17.9	32	23.9	57	42.5	15	11.2
≥55	60	0	0.0	7	11.7	19	31.7	26	43.3	8	13.3
Transmission category^e
Male-to-male sexual contact	681	35	5.1	127	18.7	259	38.1	165	24.2	95	14.0
Injection drug use
Male	11	0	0.9	2	20.4	5	46.3	3	26.9	1	5.6
Female	4	0	0.0	1	16.2	1	18.9	1	32.4	1	32.4
Male-to-male sexual contact and injection drug use	14	1	8.8	3	24.3	7	52.2	1	4.4	1	10.3
Heterosexual contact^f
Male	33	0	0.0	6	19.0	9	26.8	14	41.3	4	13.0
Female	97	2	2.1	19	19.7	29	29.9	28	28.3	20	20.0
Total^g	843	38	4.5	160	19.0	311	36.9	211	25.0	123	14.6
Black/African American
Gender
Male	10,703	683	6.4	2,353	22.0	3,364	31.4	2,088	19.5	2,215	20.7
Female	3,883	161	4.1	1,021	26.3	1,136	29.3	868	22.4	697	18.0
Transgender male-to-female^c	253	25	9.9	69	27.3	82	32.4	33	13.0	44	17.4
Transgender female-to-male^c	9	1	11.1	4	44.4	4	44.4	0	0.0	0	0.0
Additional gender identity^d	6	0	0.0	3	50.0	0	0.0	2	33.3	1	16.7
Age at diagnosis (yr)
13–24	3,904	349	8.9	977	25.0	1,398	35.8	382	9.8	798	20.4
25–34	5,144	323	6.3	1,279	24.9	1,630	31.7	845	16.4	1,067	20.7
35–44	2,453	97	4.0	522	21.3	707	28.8	662	27.0	465	19.0
45–54	1,827	54	3.0	371	20.3	461	25.2	603	33.0	338	18.5
≥55	1,526	47	3.1	301	19.7	390	25.6	499	32.7	289	18.9
Transmission category^e
Male-to-male sexual contact	8,745	629	7.2	2,020	23.1	2,833	32.4	1,458	16.7	1,805	20.6
Injection drug use
Male	333	18	5.3	60	18.0	90	27.2	88	26.3	77	23.2
Female	299	18	6.0	64	21.5	82	27.2	73	24.3	63	20.9
Male-to-male sexual contact and injection drug use	243	13	5.3	52	21.3	70	28.7	43	17.7	66	27.1
Heterosexual contact^f
Male	1,627	47	2.9	290	17.9	452	27.8	531	32.6	307	18.9
Female	3,564	144	4.0	949	26.6	1,050	29.5	790	22.2	631	17.7
Total^g	14,854	870	5.9	3,450	23.2	4,586	30.9	2,991	20.1	2,957	19.9
Hispanic/Latino^h
Gender
Male	7,526	499	6.6	1,834	24.4	2,380	31.6	1,604	21.3	1,209	16.1
Female	996	56	5.6	283	28.4	288	28.9	218	21.9	151	15.2
Transgender male-to-female^c	145	9	6.2	46	31.7	45	31.0	22	15.2	23	15.9
Transgender female-to-male^c	6	1	16.7	1	16.7	1	16.7	3	50.0	0	0.0
Additional gender identity^d	4	1	25.0	1	25.0	2	50.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	1,749	160	9.1	508	29.0	603	34.5	147	8.4	331	18.9
25–34	3,330	227	6.8	890	26.7	1,095	32.9	602	18.1	516	15.5
35–44	1,876	97	5.2	441	23.5	556	29.6	484	25.8	298	15.9
45–54	1,157	53	4.6	226	19.5	313	27.1	402	34.7	163	14.1
≥55	565	29	5.1	100	17.7	149	26.4	212	37.5	75	13.3
Transmission category^e
Male-to-male sexual contact	6,641	455	6.9	1,684	25.4	2,127	32.0	1,318	19.8	1,057	15.9
Injection drug use
Male	276	12	4.5	54	19.7	82	29.8	81	29.5	46	16.5
Female	131	6	4.5	46	35.1	31	23.7	24	18.1	24	18.6
Male-to-male sexual contact and injection drug use	302	20	6.7	76	25.1	97	32.2	49	16.3	60	19.7
Heterosexual contact^f
Male	451	20	4.4	66	14.7	119	26.3	176	39.1	70	15.4
Female	869	51	5.9	237	27.3	258	29.6	197	22.6	127	14.6
Total^g	8,677	566	6.5	2,165	25.0	2,716	31.3	1,847	21.3	1,383	15.9
Native Hawaiian/other Pacific Islander
Gender
Male	31	3	9.7	7	22.6	11	35.5	6	19.4	4	12.9
Female	8	1	12.5	0	0.0	0	0.0	5	62.5	2	25.0
Transgender male-to-female^c	2	1	50.0	0	0.0	0	0.0	1	50.0	0	0.0
Transgender female-to-male^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	9	1	11.1	4	44.4	3	33.3	0	0.0	1	11.1
25–34	18	3	16.7	1	5.6	6	33.3	5	27.8	3	16.7
35–44	9	1	11.1	2	22.2	2	22.2	3	33.3	1	11.1
45–54	4	0	0.0	0	0.0	0	0.0	3	75.0	1	25.0
≥55	1	0	0.0	0	0.0	0	0.0	1	100	0	0.0
Transmission category^e
Male-to-male sexual contact	28	3	10.1	6	21.7	10	35.7	6	21.7	3	10.8
Injection drug use
Male	2	0	8.7	1	43.5	0	4.3	0	0.0	1	43.5
Female	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Male-to-male sexual contact and injection drug use	1	1	100	0	0.0	0	0.0	0	0.0	0	0.0
Heterosexual contact^f
Male	2	0	0.0	0	0.0	1	50.0	1	50.0	0	0.0
Female	8	1	12.5	0	0.0	0	0.0	5	62.5	2	25.0
Total^g	41	5	12.2	7	17.1	11	26.8	12	29.3	6	14.6
White
Gender
Male	7,167	499	7.0	2,068	28.9	2,043	28.5	1,552	21.7	1,005	14.0
Female	1,241	78	6.3	403	32.5	287	23.1	255	20.5	218	17.6
Transgender male-to-female^c	59	11	18.6	18	30.5	16	27.1	8	13.6	6	10.2
Transgender female-to-male^c	9	1	11.1	3	33.3	5	55.6	0	0.0	0	0.0
Additional gender identity^d	2	0	0.0	2	100	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	1,270	124	9.8	434	34.2	410	32.3	101	8.0	201	15.8
25–34	2,708	225	8.3	900	33.2	796	29.4	357	13.2	430	15.9
35–44	1,702	97	5.7	516	30.3	457	26.9	413	24.3	219	12.9
45–54	1,651	72	4.4	396	24.0	419	25.4	540	32.7	224	13.6
≥55	1,147	71	6.2	248	21.6	269	23.5	404	35.2	155	13.5
Transmission category^e
Male-to-male sexual contact	5,856	430	7.3	1,684	28.8	1,685	28.8	1,237	21.1	820	14.0
Injection drug use
Male	422	22	5.2	130	30.9	108	25.6	100	23.7	62	14.7
Female	424	28	6.5	137	32.2	98	23.0	75	17.8	87	20.4
Male-to-male sexual contact and injection drug use	565	48	8.5	195	34.6	170	30.2	71	12.6	80	14.2
Heterosexual contact^f
Male	378	9	2.5	76	20.2	95	25.1	149	39.4	49	12.8
Female	823	51	6.2	269	32.7	193	23.5	179	21.7	131	15.9
Total^g	8,478	589	6.9	2,494	29.4	2,351	27.7	1,815	21.4	1,229	14.5
Multiracial
Gender
Male	839	78	9.3	224	26.7	259	30.9	159	19.0	119	14.2
Female	174	8	4.6	57	32.8	44	25.3	40	23.0	25	14.4
Transgender male-to-female^c	13	1	7.7	5	38.5	5	38.5	0	0.0	2	15.4
Transgender female-to-male^c	3	1	33.3	0	0.0	0	0.0	1	33.3	1	33.3
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	261	25	9.6	89	34.1	83	31.8	19	7.3	45	17.2
25–34	378	38	10.1	115	30.4	114	30.2	54	14.3	57	15.1
35–44	182	9	4.9	47	25.8	56	30.8	50	27.5	20	11.0
45–54	138	10	7.2	23	16.7	41	29.7	50	36.2	14	10.1
≥55	70	6	8.6	12	17.1	14	20.0	27	38.6	11	15.7
Transmission category^e
Male-to-male sexual contact	724	70	9.7	196	27.0	228	31.5	122	16.8	108	15.0
Injection drug use
Male	23	0	0.9	5	21.1	8	36.4	7	28.9	3	12.7
Female	32	2	6.5	9	26.8	8	25.2	8	24.6	5	16.8
Male-to-male sexual contact and injection drug use	48	5	9.4	16	33.7	14	28.9	9	18.9	4	9.1
Heterosexual contact^f
Male	57	4	6.9	12	21.6	14	24.2	22	38.1	5	9.2
Female	142	7	4.9	48	34.0	34	23.7	33	23.2	20	14.2
Total^g	1,029	88	8.6	286	27.8	308	29.9	200	19.4	147	14.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of HIV infection based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at diagnosis and are for cases reported to the CDC through December 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^g Includes persons whose infection were attributed to hemophila, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
^h Hispanic/Latino persons can be of any race.

Table S2. Stage of disease at HIV diagnosis during 2017 among males aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—41 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/uL or ≥ 26%)		Stage 2 (CD4 = 200-499 cells/uL or 14%-25%)		Stage 3 (AIDS) (CD4 < 200 cells/uL or OIs or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	15	2	13.2	7	45.0	5	32.5	0	0.0	1	9.3
25–34	39	3	7.7	18	45.9	9	22.4	5	12.9	4	11.1
35–44	17	1	5.8	2	10.5	8	45.6	6	33.9	1	4.1
45–54	13	1	8.0	3	24.0	4	31.2	4	28.8	1	8.0
≥55	4	0	0.0	0	0.0	0	0.0	1	25.0	3	75.0
Asian
13–24	163	11	6.8	32	19.7	77	47.4	16	9.8	27	16.3
25–34	241	13	5.4	42	17.3	100	41.4	54	22.2	33	13.6
35–44	148	5	3.3	33	22.0	52	35.2	37	25.0	21	14.4
45–54	97	6	6.0	19	19.2	22	22.7	41	42.3	10	9.8
≥55	33	0	0.0	2	6.9	9	25.5	17	52.0	5	15.6
Black/African American
13–24	3,121	306	9.8	739	23.7	1,152	36.9	296	9.5	628	20.1
25–34	3,539	247	7.0	872	24.6	1,116	31.5	551	15.6	753	21.3
35–44	1,094	41	3.7	231	21.1	314	28.7	290	26.5	217	19.8
45–54	626	22	3.5	124	19.8	150	23.9	204	32.6	127	20.2
≥55	365	14	3.9	54	14.7	100	27.4	117	32.0	80	22.0
Hispanic/Latino^c
13–24	1,482	140	9.4	429	28.9	518	35.0	113	7.6	282	19.0
25–34	2,719	191	7.0	714	26.3	910	33.5	482	17.7	422	15.5
35–44	1,375	74	5.4	337	24.5	416	30.2	343	25.0	205	14.9
45–54	779	39	5.0	152	19.5	212	27.2	264	33.8	113	14.5
≥55	287	12	4.0	53	18.4	72	25.1	116	40.5	35	12.0
Native Hawaiian/other Pacific Islander
13–24	9	1	9.1	4	45.5	3	34.1	0	0.0	1	11.4
25–34	12	2	16.7	1	8.3	5	41.7	2	16.7	2	16.7
35–44	5	0	0.0	1	20.4	2	38.8	2	40.8	0	0.0
45–54	2	0	0.0	0	0.0	0	0.0	2	100	0	0.0
≥55	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
White
13–24	977	97	9.9	306	31.4	339	34.7	86	8.8	150	15.3
25–34	1,874	155	8.3	618	33.0	560	29.9	255	13.6	286	15.3
35–44	1,094	70	6.4	330	30.2	296	27.0	273	25.0	125	11.4
45–54	1,157	53	4.6	270	23.3	308	26.7	369	31.9	156	13.5
≥55	754	55	7.3	160	21.2	182	24.1	254	33.7	103	13.7
Multiracial
13–24	207	22	10.5	60	29.0	72	34.9	17	8.1	37	17.6
25–34	296	32	10.9	87	29.5	89	30.1	42	14.2	45	15.2
35–44	113	7	6.2	31	27.2	36	32.1	25	22.0	14	12.5
45–54	77	6	8.3	14	17.7	25	32.2	25	31.9	8	9.9
≥55	31	3	9.7	4	12.9	5	17.5	13	43.4	5	16.5
All
13–24	5,974	577	9.7	1,578	26.4	2,167	36.3	527	8.8	1,125	18.8
25–34	8,720	643	7.4	2,352	27.0	2,789	32.0	1,391	15.9	1,546	17.7
35–44	3,845	198	5.1	965	25.1	1,123	29.2	976	25.4	583	15.2
45–54	2,751	127	4.6	580	21.1	721	26.2	908	33.0	414	15.0
≥55	1,474	84	5.7	272	18.5	368	24.9	519	35.2	231	15.7
Total	22,763	1,630	7.2	5,746	25.2	7,167	31.5	4,321	19.0	3,899	17.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of HIV infection based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at diagnosis and are for cases reported to the CDC through December 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c Hispanic/Latino persons can be of any race.

Table S3. Linkage to HIV medical care and viral suppression within 6 months of HIV diagnosis during 2017, among persons aged ≥13 years, by race/ethnicity and selected characteristics—41 states and the District of Columbia
		Linkage to Care								Viral Suppression
		≤1 month				≤3 months
		≥1 CD4 or VL tests		No CD4 or VL test		≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	121	99	81.8	22	18.2	106	87.6	15	12.4	81	66.9
Female	35	31	88.6	4	11.4	31	88.6	4	11.4	22	62.9
Transgender male-to-female^a	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Transgender female-to-male^a	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	20	17	85.0	3	15.0	17	85.0	3	15.0	13	65.0
25–34	64	54	84.4	10	15.6	58	90.6	6	9.4	41	64.1
35–44	33	27	81.8	6	18.2	28	84.8	5	15.2	25	75.8
45–54	28	26	92.9	2	7.1	28	100	0	0.0	21	75.0
≥55	11	6	54.5	5	45.5	6	54.5	5	45.5	3	27.3
Transmission category^c
Male-to-male sexual contact	88	74	84.7	13	15.3	79	90.4	8	9.6	61	69.1
Injection drug use
Male	9	8	80.9	2	19.1	8	80.9	2	19.1	4	46.8
Female	12	11	89.0	1	11.0	11	89.0	1	11.0	6	49.2
Male-to-male sexual contact and injection drug use	18	14	78.0	4	22.0	16	89.3	2	10.7	13	71.2
Heterosexual contact^d
Male	6	3	54.0	3	46.0	3	54.0	3	46.0	3	54.0
Female	23	21	88.4	3	11.6	21	88.4	3	11.6	16	69.8
Total^e	156	130	83.3	26	16.7	137	87.8	19	12.2	103	66.0
Asian
Gender
Male	724	591	81.6	133	18.4	642	88.7	82	11.3	523	72.2
Female	100	76	76.0	24	24.0	82	82.0	18	18.0	73	73.0
Transgender male-to-female^a	16	14	87.5	2	12.5	15	93.8	1	6.3	9	56.3
Transgender female-to-male^a	2	2	100	0	0.0	2	100	0	0.0	2	100
Additional gender identity^b	1	1	100	0	0.0	1	100	0	0.0	1	100
Age at diagnosis (yr)
13–24	175	138	78.9	37	21.1	152	86.9	23	13.1	125	71.4
25–34	274	232	84.7	42	15.3	243	88.7	31	11.3	202	73.7
35–44	200	155	77.5	45	22.5	175	87.5	25	12.5	145	72.5
45–54	134	109	81.3	25	18.7	119	88.8	15	11.2	93	69.4
≥55	60	50	83.3	10	16.7	53	88.3	7	11.7	43	71.7
Transmission category^c
Male-to-male sexual contact	681	555	81.5	126	18.5	602	88.4	79	11.6	492	72.2
Injection drug use
Male	11	8	74.1	3	25.9	10	94.4	1	5.6	8	72.2
Female	4	2	64.9	1	35.1	3	67.6	1	32.4	2	59.5
Male-to-male sexual contact and injection drug use	14	13	93.4	1	6.6	13	94.9	1	5.1	10	70.6
Heterosexual contact^d
Male	33	28	84.0	5	16.0	31	91.9	3	8.1	22	66.9
Female	97	75	77.0	22	23.0	81	83.1	17	16.9	72	74.1
Total^e	843	684	81.1	159	18.9	742	88.0	101	12.0	608	72.1
Black/African American
Gender
Male	10,703	7,933	74.1	2,770	25.9	8,919	83.3	1,784	16.7	6,040	56.4
Female	3,883	3,037	78.2	846	21.8	3,372	86.8	511	13.2	2,542	65.5
Transgender male-to-female^a	253	195	77.1	58	22.9	215	85.0	38	15.0	152	60.1
Transgender female-to-male^a	9	9	100	0	0.0	9	100	0	0.0	7	77.8
Additional gender identity^b	6	6	100	0	0.0	6	100	0	0.0	4	66.7
Age at diagnosis (yr)
13–24	3,904	2,867	73.4	1,037	26.6	3,257	83.4	647	16.6	2,210	56.6
25–34	5,144	3,821	74.3	1,323	25.7	4,299	83.6	845	16.4	3,036	59.0
35–44	2,453	1,880	76.6	573	23.4	2,080	84.8	373	15.2	1,506	61.4
45–54	1,827	1,418	77.6	409	22.4	1,561	85.4	266	14.6	1,122	61.4
≥55	1,526	1,194	78.2	332	21.8	1,324	86.8	202	13.2	871	57.1
Transmission category^c
Male-to-male sexual contact	8,745	6,485	74.2	2,260	25.8	7,301	83.5	1,444	16.5	4,984	57.0
Injection drug use
Male	333	243	73.1	89	26.9	268	80.4	65	19.6	162	48.7
Female	299	231	77.2	68	22.8	251	83.7	49	16.3	164	54.7
Male-to-male sexual contact and injection drug use	243	168	69.2	75	30.8	187	76.8	56	23.2	123	50.6
Heterosexual contact^d
Male	1,627	1,227	75.4	400	24.6	1,373	84.4	254	15.6	920	56.5
Female	3,564	2,790	78.3	774	21.7	3,104	87.1	461	12.9	2,367	66.4
Total^e	14,854	11,180	75.3	3,674	24.7	12,521	84.3	2,333	15.7	8,745	58.9
Hispanic/Latino^h
Gender
Male	7,526	5,907	78.5	1,619	21.5	6,502	86.4	1,024	13.6	4,901	65.1
Female	996	781	78.4	215	21.6	873	87.7	123	12.3	637	64.0
Transgender male-to-female^a	145	106	73.1	39	26.9	125	86.2	20	13.8	95	65.5
Transgender female-to-male^a	6	6	100	0	0.0	6	100	0	0.0	4	66.7
Additional gender identity^b	4	3	75.0	1	25.0	4	100	0	0.0	3	75.0
Age at diagnosis (yr)
13–24	1,749	1,286	73.5	463	26.5	1,469	84.0	280	16.0	1,074	61.4
25–34	3,330	2,608	78.3	722	21.7	2,894	86.9	436	13.1	2,182	65.5
35–44	1,876	1,502	80.1	374	19.9	1,616	86.1	260	13.9	1,256	67.0
45–54	1,157	941	81.3	216	18.7	1,026	88.7	131	11.3	761	65.8
≥55	565	466	82.5	99	17.5	505	89.4	60	10.6	367	65.0
Transmission category^c
Male-to-male sexual contact	6,641	5,220	78.6	1,421	21.4	5,750	86.6	891	13.4	4,385	66.0
Injection drug use
Male	276	221	80.3	54	19.7	236	85.8	39	14.2	151	54.9
Female	131	97	74.5	33	25.5	111	85.2	19	14.8	65	50.0
Male-to-male sexual contact and injection drug use	302	219	72.5	83	27.5	251	83.0	51	17.0	162	53.7
Heterosexual contact^d
Male	451	351	77.8	100	22.2	389	86.3	62	13.7	297	65.9
Female	869	687	79.1	182	20.9	765	88.1	104	11.9	575	66.2
Total^e	8,677	6,803	78.4	1,874	21.6	7,510	86.6	1,167	13.4	5,640	65.0
Native Hawaiian/other Pacific Islander
Gender
Male	31	24	77.4	7	22.6	28	90.3	3	9.7	17	54.8
Female	8	7	87.5	1	12.5	8	100	0	0.0	7	87.5
Transgender male-to-female^a	2	2	100	0	0.0	2	100	0	0.0	0	0.0
Transgender female-to-male^a	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	9	7	77.8	2	22.2	8	88.9	1	11.1	3	33.3
25–34	18	15	83.3	3	16.7	17	94.4	1	5.6	12	66.7
35–44	9	7	77.8	2	22.2	9	100	0	0.0	6	66.7
45–54	4	3	75.0	1	25.0	3	75.0	1	25.0	2	50.0
≥55	1	1	100	0	0.0	1	100	0	0.0	1	100
Transmission category^c
Male-to-male sexual contact	28	23	82.7	5	17.3	26	92.8	2	7.2	16	57.4
Injection drug use
Male	2	0	4.3	2	95.7	1	56.5	1	43.5	0	4.3
Female	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Male-to-male sexual contact and injection drug use	1	1	100	0	0.0	1	100	0	0.0	0	0.0
Heterosexual contact^d
Male	2	2	100	0	0.0	2	100	0	0.0	1	50.0
Female	8	7	87.5	1	12.5	8	100	0	0.0	7	87.5
Total^e	41	33	80.5	8	19.5	38	92.7	3	7.3	24	58.5
White
Gender
Male	7,167	5,843	81.5	1,324	18.5	6,426	89.7	741	10.3	4,857	67.8
Female	1,241	964	77.7	277	22.3	1,071	86.3	170	13.7	735	59.2
Transgender male-to-female^a	59	47	79.7	12	20.3	55	93.2	4	6.8	43	72.9
Transgender female-to-male^a	9	8	88.9	1	11.1	9	100	0	0.0	8	88.9
Additional gender identity^b	2	2	100	0	0.0	2	100	0	0.0	2	100
Age at diagnosis (yr)
13–24	1,270	994	78.3	276	21.7	1,126	88.7	144	11.3	828	65.2
25–34	2,708	2,115	78.1	593	21.9	2,370	87.5	338	12.5	1,758	64.9
35–44	1,702	1,397	82.1	305	17.9	1,533	90.1	169	9.9	1,116	65.6
45–54	1,651	1,388	84.1	263	15.9	1,485	89.9	166	10.1	1,146	69.4
≥55	1,147	970	84.6	177	15.4	1,049	91.5	98	8.5	797	69.5
Transmission category^c
Male-to-male sexual contact	5,856	4,828	82.4	1,028	17.6	5,277	90.1	579	9.9	4,075	69.6
Injection drug use
Male	422	321	76.1	101	23.9	369	87.6	52	12.4	236	56.0
Female	424	321	75.9	102	24.1	354	83.7	69	16.3	199	47.0
Male-to-male sexual contact and injection drug use	565	433	76.6	132	23.4	493	87.3	72	12.7	337	59.6
Heterosexual contact^d
Male	378	304	80.4	74	19.6	337	89.1	41	10.9	250	66.2
Female	823	648	78.7	175	21.3	722	87.8	101	12.2	542	65.8
Total^e	8,478	6,864	81.0	1,614	19.0	7,563	89.2	915	10.8	5,645	66.6
Multiracial
Gender
Male	839	674	80.3	165	19.7	739	88.1	100	11.9	552	65.8
Female	174	136	78.2	38	21.8	157	90.2	17	9.8	118	67.8
Transgender male-to-female^a	13	11	84.6	2	15.4	13	100	0	0.0	6	46.2
Transgender female-to-male^a	3	2	66.7	1	33.3	2	66.7	1	33.3	3	100
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	261	205	78.5	56	21.5	226	86.6	35	13.4	162	62.1
25–34	378	298	78.8	80	21.2	332	87.8	46	12.2	257	68.0
35–44	182	148	81.3	34	18.7	162	89.0	20	11.0	127	69.8
45–54	138	117	84.8	21	15.2	129	93.5	9	6.5	94	68.1
≥55	70	55	78.6	15	21.4	62	88.6	8	11.4	39	55.7
Transmission category^c
Male-to-male sexual contact	724	581	80.2	143	19.8	637	87.9	88	12.1	488	67.4
Injection drug use
Male	23	19	82.0	4	18.0	20	87.3	3	12.7	13	55.3
Female	32	21	66.7	11	33.3	27	85.0	5	15.0	18	56.4
Male-to-male sexual contact and injection drug use	48	41	85.0	7	15.0	44	91.3	4	8.7	26	54.5
Heterosexual contact^d
Male	57	44	78.2	12	21.8	51	90.8	5	9.2	31	54.5
Female	142	114	80.2	28	19.8	129	90.8	13	9.2	101	71.4
Total^e	1,029	823	80.0	206	20.0	911	88.5	118	11.5	679	66.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis and are for cases reported to the CDC as of December 2019. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2017. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico of .

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^d Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^e Includes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
^f Hispanic/Latino persons can be of any race.

Table S4. Linkage to HIV medical care and viral suppression within 6 months of HIV diagnosis during 2017, among males aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—41 states and the District of Columbia
		Linkage to Care								Viral Suppression
		≤1 month				≤3 months
		≥1 CD4 or VL tests		No CD4 or VL test		≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	15	14	90.7	1	9.3	14	90.7	1	9.3	11	72.2
25–34	39	33	83.8	6	16.2	36	91.5	3	8.5	26	65.7
35–44	17	16	95.9	1	4.1	16	95.9	1	4.1	15	90.1
45–54	13	11	84.0	2	16.0	13	100	0	0.0	8	61.6
≥55	4	1	25.0	3	75.0	1	25.0	3	75.0	1	25.0
Asian
13–24	163	128	78.7	35	21.3	142	87.3	21	12.7	117	72.0
25–34	241	204	84.6	37	15.4	213	88.3	28	11.7	177	73.5
35–44	148	116	78.4	32	21.6	132	89.2	16	10.8	109	73.6
45–54	97	80	83.3	16	16.7	87	90.2	10	9.8	66	68.1
≥55	33	27	82.0	6	18.0	29	87.1	4	12.9	23	69.7
Black/African American
13–24	3,121	2,284	73.2	837	26.8	2,604	83.4	517	16.6	1,735	55.6
25–34	3,539	2,599	73.4	940	26.6	2,939	83.0	600	17.0	2,038	57.6
35–44	1,094	840	76.8	254	23.2	915	83.7	178	16.3	646	59.0
45–54	626	484	77.3	142	22.7	533	85.1	93	14.9	381	60.9
≥55	365	278	76.3	86	23.7	310	85.0	55	15.0	184	50.4
Hispanic/Latino^a
13–24	1,482	1,086	73.3	396	26.7	1,245	84.0	237	16.0	920	62.1
25–34	2,719	2,147	79.0	572	21.0	2,365	87.0	354	13.0	1,802	66.3
35–44	1,375	1,114	81.1	260	18.9	1,197	87.1	178	12.9	947	68.9
45–54	779	632	81.2	147	18.8	683	87.6	96	12.4	525	67.3
≥55	287	240	83.7	47	16.3	260	90.6	27	9.4	191	66.4
Native Hawaiian/other Pacific Islander
13–24	9	7	79.5	2	20.5	8	88.6	1	11.4	3	34.1
25–34	12	9	75.0	3	25.0	11	91.7	1	8.3	7	58.3
35–44	5	5	100	0	0.0	5	100	0	0.0	5	100
45–54	2	2	100	0	0.0	2	100	0	0.0	1	50.0
≥55	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
White
13–24	977	771	78.9	206	21.1	871	89.1	106	10.9	650	66.6
25–34	1,874	1,502	80.1	373	19.9	1,663	88.7	212	11.3	1,290	68.8
35–44	1,094	928	84.9	166	15.1	1,008	92.1	87	7.9	776	71.0
45–54	1,157	988	85.4	169	14.6	1,045	90.3	112	9.7	820	70.9
≥55	754	639	84.7	115	15.3	691	91.6	63	8.4	538	71.3
Multiracial
13–24	207	163	78.4	45	21.6	178	85.6	30	14.4	134	64.8
25–34	296	233	78.9	63	21.1	259	87.6	37	12.4	202	68.2
35–44	113	94	83.9	18	16.1	98	87.5	14	12.5	85	75.6
45–54	77	65	83.5	13	16.5	74	95.0	4	5.0	49	63.4
≥55	31	26	83.5	5	16.5	28	90.0	3	10.0	18	57.6
All
13–24	5,974	4,452	74.5	1,521	25.5	5,061	84.7	913	15.3	3,572	59.8
25–34	8,720	6,726	77.1	1,994	22.9	7,485	85.8	1,235	14.2	5,541	63.5
35–44	3,845	3,114	81.0	731	19.0	3,371	87.7	473	12.3	2,583	67.2
45–54	2,751	2,262	82.2	489	17.8	2,436	88.6	315	11.4	1,850	67.3
≥55	1,474	1,212	82.2	263	17.8	1,319	89.5	155	10.5	954	64.7
Total	22,763	17,766	78.0	4,997	22.0	19,672	86.4	3,091	13.6	14,500	63.7

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis and are for cases reported to CDC through December 2019. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

^a Hispanic/Latino persons can be of any race.

Table S5. Receipt of HIV medical care and viral suppression among persons aged ≥13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by race/ethnicity and selected characteristics—41 states and the District of Columbia
	Persons alive at year-end 2017	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	1,449	1,091	75.3	817	56.4	941	64.9
Female	586	443	75.6	335	57.2	341	58.2
Transgender male-to-female^c	24	19	79.2	15	62.5	14	58.3
Transgender female-to-male^c	4	4	100	3	75.0	3	75.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0
Age at year-end 2017 (yr)
13–24	78	62	79.5	49	62.8	53	67.9
25–34	354	277	78.2	200	56.5	218	61.6
35–44	465	336	72.3	247	53.1	279	60.0
45–54	649	503	77.5	370	57.0	412	63.5
≥55	517	379	73.3	304	58.8	337	65.2
Transmission category^e
Male-to-male sexual contact	1,007	774	76.9	586	58.2	678	67.3
Injection drug use
Male	153	102	66.6	72	47.2	79	51.9
Female	189	137	72.5	102	54.2	101	53.3
Male-to-male sexual contact and injection drug use	182	135	74.2	106	58.1	112	61.7
Heterosexual contact^f
Male	117	88	75.3	60	50.8	76	64.4
Female	385	302	78.3	227	59.0	236	61.3
Other^g
Male	14	11	78.8	9	62.0	10	70.8
Female	16	8	53.2	8	52.5	7	46.2
Total	2,063	1,557	75.5	1,170	56.7	1,299	63.0
Asian^h
Gender
Male	9,784	7,387	75.5	5,774	59.0	6,781	69.3
Female	2,087	1,514	72.5	1,179	56.5	1,373	65.8
Transgender male-to-female^c	132	105	79.5	80	60.6	92	69.7
Transgender female-to-male^c	2	2	100	2	100	2	100
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0
Age at year-end 2017 (yr)
13–24	440	356	80.9	290	65.9	325	73.9
25–34	2,208	1,683	76.2	1,259	57.0	1,526	69.1
35–44	3,415	2,564	75.1	1,976	57.9	2,359	69.1
45–54	3,506	2,674	76.3	2,102	60.0	2,447	69.8
≥55	2,436	1,731	71.1	1,408	57.8	1,591	65.3
Transmission category^e
Male-to-male sexual contact	8,302	6,328	76.2	4,909	59.1	5,820	70.1
Injection drug use
Male	365	233	63.9	192	52.7	210	57.4
Female	151	99	65.9	82	54.7	88	58.6
Male-to-male sexual contact and injection drug use	345	270	78.2	209	60.7	241	69.8
Heterosexual contact^f
Male	813	597	73.4	498	61.3	549	67.6
Female	1,863	1,366	73.3	1,057	56.8	1,241	66.6
Other^g
Male	91	65	70.9	45	49.6	54	58.8
Female	76	51	67.2	41	54.4	45	60.0
Total	12,005	9,008	75.0	7,035	58.6	8,248	68.7
Black/African American
Gender
Male	230,105	165,855	72.1	125,740	54.6	130,781	56.8
Female	120,358	89,371	74.3	68,226	56.7	71,365	59.3
Transgender male-to-female^c	3,812	3,111	81.6	2,399	62.9	2,246	58.9
Transgender female-to-male^c	148	121	81.8	95	64.2	86	58.1
Additional gender identity^d	57	45	78.9	37	64.9	31	54.4
Age at year-end 2017 (yr)
13–24	18,070	13,632	75.4	9,883	54.7	9,550	52.9
25–34	64,920	47,601	73.3	33,841	52.1	34,416	53.0
35–44	69,899	50,930	72.9	37,357	53.4	39,302	56.2
45–54	100,609	74,431	74.0	57,812	57.5	60,418	60.1
≥55	100,982	71,909	71.2	57,604	57.0	60,823	60.2
Transmission category^e
Male-to-male sexual contact	147,709	109,559	74.2	81,631	55.3	86,203	58.4
Injection drug use
Male	27,628	17,502	63.3	13,870	50.2	13,930	50.4
Female	20,163	14,637	72.6	11,295	56.0	11,576	57.4
Male-to-male sexual contact and injection drug use	13,836	10,529	76.1	8,307	60.0	8,044	58.1
Heterosexual contact^f
Male	41,838	29,382	70.2	22,813	54.5	23,506	56.2
Female	96,935	72,311	74.6	55,034	56.8	58,193	60.0
Other^g
Male	2,953	2,031	68.8	1,548	52.4	1,368	46.3
Female	3,418	2,552	74.7	1,999	58.5	1,689	49.4
Total	354,480	258,503	72.9	196,497	55.4	204,509	57.7
Hispanic/Latinoⁱ
Gender
Male	150,473	107,881	71.7	86,733	57.6	93,408	62.1
Female	36,112	27,607	76.4	22,509	62.3	23,145	64.1
Transgender male-to-female^c	2,706	2,242	82.9	1,857	68.6	1,791	66.2
Transgender female-to-male^c	60	48	80.0	40	66.7	39	65.0
Additional gender identity^d	37	33	89.2	30	81.1	24	64.9
Age at year-end 2017 (yr)
13–24	6,963	5,471	78.6	4,163	59.8	4,265	61.3
25–34	32,014	24,417	76.3	18,462	57.7	19,852	62.0
35–44	44,488	31,704	71.3	24,981	56.2	26,932	60.5
45–54	58,882	42,931	72.9	35,125	59.7	37,483	63.7
≥55	47,041	33,288	70.8	28,438	60.5	29,875	63.5
Transmission category^e
Male-to-male sexual contact	112,530	83,152	73.9	66,481	59.1	73,029	64.9
Injection drug use
Male	15,809	9,325	59.0	7,797	49.3	7,683	48.6
Female	7,904	5,907	74.7	4,895	61.9	4,753	60.1
Male-to-male sexual contact and injection drug use	10,857	8,326	76.7	6,728	62.0	6,607	60.9
Heterosexual contact^f
Male	12,629	8,348	66.1	6,847	54.2	7,203	57.0
Female	26,946	20,705	76.8	16,813	62.4	17,710	65.7
Other^g
Male	1,385	999	72.1	761	54.9	699	50.4
Female	1,329	1,048	78.9	847	63.7	724	54.4
Total	189,388	137,811	72.8	111,169	58.7	118,407	62.5
Native Hawaiian/other Pacific Islander
Gender
Male	556	420	75.5	308	55.4	365	65.6
Female	116	82	70.7	58	50.0	73	62.9
Transgender male-to-female^c	20	18	90.0	13	65.0	16	80.0
Transgender female-to-male^c	0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0
Age at year-end 2017 (yr)
13–24	20	12	60.0	8	40.0	11	55.0
25–34	129	101	78.3	68	52.7	80	62.0
35–44	182	133	73.1	91	50.0	119	65.4
45–54	209	157	75.1	114	54.5	134	64.1
≥55	152	117	77.0	98	64.5	110	72.4
Transmission category^e
Male-to-male sexual contact	490	367	74.8	267	54.4	325	66.2
Injection drug use
Male	19	15	80.0	12	63.2	11	56.8
Female	20	13	64.0	11	56.3	12	62.4
Male-to-male sexual contact and injection drug use	37	34	92.1	23	63.6	26	70.4
Heterosexual contact^f
Male	28	20	72.5	17	61.1	18	64.3
Female	96	69	72.2	47	48.8	60	63.1
Other^g
Male	3	2	92.0	2	92.0	2	84.0
Female	1	0	50.0	0	33.3	0	50.0
Total	692	520	75.1	379	54.8	454	65.6
White
Gender
Male	220,381	175,754	79.8	132,737	60.2	156,585	71.1
Female	31,758	23,634	74.4	17,499	55.1	19,865	62.6
Transgender male-to-female^c	826	709	85.8	546	66.1	579	70.1
Transgender female-to-male^c	63	53	84.1	41	65.1	41	65.1
Additional gender identity^d	20	17	85.0	12	60.0	15	75.0
Age at year-end 2017 (yr)
13–24	3,991	3,187	79.9	2,310	57.9	2,638	66.1
25–34	24,998	19,775	79.1	13,837	55.4	16,503	66.0
35–44	39,282	30,844	78.5	22,109	56.3	26,196	66.7
45–54	87,995	70,270	79.9	52,480	59.6	62,277	70.8
≥55	96,782	76,091	78.6	60,099	62.1	69,471	71.8
Transmission category^e
Male-to-male sexual contact	182,457	146,485	80.3	110,589	60.6	132,047	72.4
Injection drug use
Male	10,437	7,339	70.3	5,607	53.7	6,111	58.6
Female	9,808	7,090	72.3	5,282	53.9	5,709	58.2
Male-to-male sexual contact and injection drug use	19,242	15,765	81.9	11,996	62.3	13,065	67.9
Heterosexual contact^f
Male	7,499	5,687	75.8	4,246	56.6	4,906	65.4
Female	21,118	15,960	75.6	11,786	55.8	13,662	64.7
Other^g
Male	1,587	1,200	75.6	854	53.8	1,046	65.9
Female	900	641	71.2	475	52.8	538	59.7
Total	253,048	200,167	79.1	150,835	59.6	177,085	70.0
Multiracial
Gender
Male	30,503	26,136	85.7	19,986	65.5	21,548	70.6
Female	9,318	8,008	85.9	6,220	66.8	6,349	68.1
Transgender male-to-female^c	644	580	90.1	462	71.7	425	66.0
Transgender female-to-male^c	24	24	100	17	70.8	17	70.8
Additional gender identity^d	13	13	100	9	69.2	10	76.9
Age at year-end 2017 (yr)
13–24	1,671	1,384	82.8	1,016	60.8	986	59.0
25–34	7,048	5,738	81.4	4,120	58.5	4,380	62.1
35–44	8,301	6,979	84.1	5,191	62.5	5,517	66.5
45–54	12,582	10,966	87.2	8,523	67.7	9,044	71.9
≥55	10,900	9,694	88.9	7,844	72.0	8,422	77.3
Transmission category^e
Male-to-male sexual contact	22,608	19,277	85.3	14,577	64.5	16,130	71.3
Injection drug use
Male	2,175	1,878	86.3	1,542	70.9	1,508	69.3
Female	2,383	2,077	87.1	1,651	69.3	1,609	67.5
Male-to-male sexual contact and injection drug use	3,628	3,250	89.6	2,556	70.5	2,503	69.0
Heterosexual contact^f
Male	2,357	1,995	84.7	1,540	65.3	1,605	68.1
Female	6,620	5,660	85.5	4,353	65.7	4,554	68.8
Other^g
Male	391	328	83.7	241	61.7	235	60.1
Female	339	296	87.3	234	69.1	205	60.4
Total	40,502	34,761	85.8	26,694	65.9	28,349	70.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2017 (i.e., most recent known address). Data are for cases reported to the CDC through December 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.

^a Performed ≥3 months apart during 2017.
^b VL test results are from the most recent test during 2017.
^c “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^g Includes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or risk factor not reported or not identified.
^h Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^I Hispanic/Latino persons can be of any race.

Table S6. Receipt of HIV medical care and viral suppression during 2017 among males aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age group—41 states and the District of Columbia
	Males alive at year-end 2017	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	53	46	87.0	36	67.1	40	75.6
25–34	227	185	81.5	133	58.7	156	68.5
35–44	215	156	72.7	111	51.7	142	66.2
45–54	304	230	75.8	178	58.6	199	65.7
≥55	209	157	75.0	128	61.6	141	67.6
Asian^c
13–24	330	265	80.4	212	64.4	246	74.6
25–34	1,727	1,317	76.2	973	56.3	1,203	69.7
35–44	2,269	1,728	76.1	1,323	58.3	1,592	70.1
45–54	2,460	1,904	77.4	1,497	60.8	1,745	70.9
≥55	1,516	1,115	73.5	903	59.6	1,034	68.2
Black/African American
13–24	11,397	8,696	76.3	6,164	54.1	6,291	55.2
25–34	42,930	32,202	75.0	22,796	53.1	23,648	55.1
35–44	29,302	21,850	74.6	16,111	55.0	17,134	58.5
45–54	36,912	27,382	74.2	21,182	57.4	22,561	61.1
≥55	27,168	19,429	71.5	15,378	56.6	16,568	61.0
Hispanic/Latino^d
13–24	4,750	3,769	79.3	2,843	59.8	3,059	64.4
25–34	23,909	18,507	77.4	14,010	58.6	15,461	64.7
35–44	28,517	20,474	71.8	16,211	56.8	17,883	62.7
45–54	34,242	25,200	73.6	20,516	59.9	22,610	66.0
≥55	21,111	15,202	72.0	12,901	61.1	14,016	66.4
Native Hawaiian/other Pacific Islander
13–24	13	7	54.3	5	38.8	6	46.5
25–34	100	78	77.6	51	50.8	65	64.7
35–44	138	101	73.2	70	50.7	92	66.6
45–54	140	104	74.2	79	56.0	91	65.0
≥55	99	77	77.7	62	62.9	71	71.3
White
13–24	2,517	2,042	81.1	1,470	58.4	1,754	69.7
25–34	17,822	14,269	80.1	9,977	56.0	12,358	69.3
35–44	26,509	21,143	79.8	15,116	57.0	18,505	69.8
45–54	63,812	51,595	80.9	38,558	60.4	46,559	73.0
≥55	71,797	57,436	80.0	45,468	63.3	52,871	73.6
Multiracial
13–24	1,025	845	82.5	604	58.9	624	60.8
25–34	5,000	4,085	81.7	2,914	58.3	3,227	64.5
35–44	4,746	3,988	84.0	2,934	61.8	3,256	68.6
45–54	6,842	5,914	86.4	4,561	66.7	5,088	74.4
≥55	4,995	4,444	89.0	3,564	71.3	3,936	78.8
All races
13–24	20,085	15,669	78.0	11,333	56.4	12,020	59.8
25–34	91,715	70,643	77.0	50,854	55.4	56,117	61.2
35–44	91,714	69,441	75.7	51,879	56.6	58,605	63.9
45–54	144,836	112,344	77.6	86,582	59.8	98,868	68.3
≥55	127,086	97,882	77.0	78,423	61.7	88,658	69.8
Total	475,435	365,980	77.0	279,071	58.7	314,269	66.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note: Data are based on address of residence as of December 31, 2017 (i.e., most recent known address). Data are for cases reported to the CDC through December 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.

^aPerformed ≥3 months apart during 2017.
^b VL test results are from the most recent test during 2017.
^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^d Hispanic/Latino persons can be of any race.

Table S7a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017 and 2018, among persons aged ≥16 years, by selected characteristics—United States
	2017			2018
	No. prescribed PrEP^a	No. with PrEP indications^b	PrEP coverage^c (%)	No. prescribed PrEP^a	No. with PrEP indications^b	PrEP coverage^c (%)
Sex at birth
Male	149,620	993,840	15.1	210,427	989,200	21.3
Female	11,458	227,240	5.0	15,995	227,010	7.0
Age (yr)
16–24	20,071	259,130	7.7	29,743	246,290	12.1
25–34	64,906	425,690	15.2	92,924	434,680	21.4
35–44	38,088	233,560	16.3	52,576	238,470	22.0
45–54	25,252	180,870	14.0	32,775	173,420	18.9
≥55	12,868	121,830	10.6	18,523	123,350	15.0
Race/ethnicity^d
Other	7,149	132,040	5.4	9,836	131,180	7.5
Black/African American	20,255	475,100	4.3	29,262	468,540	6.2
Hispanic/Latino^e	23,142	299,580	7.7	34,228	312,820	7.5
White	110,638	311,250	35.5	153,215	300,650	51.0
Total	161,185	1,221,080	13.2	226,541	1,216,210	18.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; NHSS, National HIV Surveillance System [footnotes only].

^a Estimated using data from IQVIA pharmacy database through September 2020 and based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.
^b Estimated using 2017 and 2018 data from NHSS, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; therefore, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data and 2018 denominators were used for 2018 PrEP coverage data.
^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
^d Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted by applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
^e Hispanic/Latino persons can be of any race.

Table S7b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017 and 2018, among persons aged ≥16 years, by area of residence—United States and Puerto Rico
	2017			2018
Area of residence	Persons prescribed PrEP^a	Persons with PrEP indications^b	PrEP coverage^c (%)	Persons prescribed PrEP^a	Persons with PrEP indications^b	PrEP coverage^c (%)
Alabama	1,014	11,390	8.9	1,557	11,020	14.1
Alaska	120	2,370	5.1	196	1,780	11.0
Arizona	2,430	26,820	9.1	3,694	25,780	14.3
Arkansas	445	4,840	9.2	632	5,130	12.3
California	28,138	166,150	16.9	37,659	165,030	22.8
Colorado	2,484	25,510	9.7	3,517	25,120	14.0
Connecticut	1,636	10,970	14.9	2,349	9,560	24.6
Delaware	287	4,860	5.9	423	4,400	9.6
District of Columbia	4,018	13,710	29.3	5,212	12,950	40.2
Florida	8,731	125,160	7.0	14,999	125,330	12.0
Georgia	4,685	40,680	11.5	6,548	39,030	16.8
Hawaii	460	5,440	8.5	698	4,360	16.0
Idaho	272	3,860	7.0	380	4,790	7.9
Illinois	10,605	54,620	19.4	14,334	55,860	25.7
Indiana	1,577	21,640	7.3	2,251	22,170	10.2
Iowa	803	4,280	18.8	1,186	4,760	24.9
Kansas	556	5,570	10.0	751	5,060	14.8
Kentucky	781	13,170	5.9	1,244	12,990	9.6
Louisiana	2,458	15,490	15.9	3,574	15,920	22.4
Maine	318	3,270	9.7	494	3,950	12.5
Maryland	2,815	28,150	10.0	4,089	27,300	15.0
Massachusetts	5,996	25,110	23.9	8,191	24,900	32.9
Michigan	2,307	28,520	8.1	3,544	29,570	12.0
Minnesota	2,581	23,770	10.9	3,552	21,720	16.4
Mississippi	465	5,030	9.2	655	4,530	14.5
Missouri	1,983	19,420	10.2	2,850	18,370	15.5
Montana	123	2,750	4.5	185	2,290	8.1
Nebraska	361	2,590	13.9	481	2,180	22.1
Nevada	1,127	10,870	10.4	1,564	11,390	13.7
New Hampshire	338	3,110	10.9	533	3,020	17.6
New Jersey	3,457	28,590	12.1	4,768	25,280	18.9
New Mexico	618	6,720	9.2	820	6,800	12.1
New York	23,455	74,450	31.5	30,945	72,640	42.6
North Carolina	2,736	33,110	8.3	4,158	32,490	12.8
North Dakota	111	1,230	9.0	164	1,520	10.8
Ohio	3,645	40,940	8.9	4,931	40,320	12.2
Oklahoma	555	11,030	5.0	860	11,030	7.8
Oregon	2,073	20,720	10.0	2,757	19,750	14.0
Pennsylvania	6,326	36,160	17.5	8,800	36,490	24.1
Rhode Island	657	4,360	15.1	897	3,880	23.1
South Carolina	720	10,390	6.9	1,249	10,390	12.0
South Dakota	60	1,000	6.0	104	910	11.4
Tennessee	1,802	22,890	7.9	2,691	22,460	12.0
Texas	11,750	123,400	9.5	18,050	123,790	14.6
Utah	1,045	6,900	15.1	1,500	6,840	21.9
Vermont	216	1,490	14.5	288	1,060	27.2
Virginia	2,167	33,670	6.4	3,267	31,430	10.4
Washington	6,952	35,600	19.5	8,986	40,050	22.4
West Virginia	242	3,660	6.6	380	5,250	7.2
Wisconsin	1,428	14,230	10.0	2,021	12,980	15.6
Wyoming	50	1,410	3.5	80	890	9.0
Puerto Rico^d	120	9,700	1.2	245	9,700	2.5
Total	161,185	1,221,080	13.2	226,541	1,216,210	18.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; NHSS, National HIV Surveillance System [footnotes only].

^a Estimated using data from IQVIA pharmacy database and based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.
^b Estimated using 2017 and 2018 data from NHSS, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; therefore, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data and 2018 denominators were used for 2018 PrEP coverage data.
^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
^d Number of persons with PrEP indications in Puerto Rico was unavailable in 2017 and 2018 data is used for 2017.

Table S8a. Stage 3 (AIDS) at the time of diagnosis of HIV infection among adults aged ≥50 years, by year of diagnosis and selected characteristics, 2015-2019—United States
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender
Male	4,901	1,837	37.5	4,765	1,815	38.1	4,637	1,699	36.6	4,433	1,615	36.4	4,320	1,549	35.9
Female	1,792	596	33.3	1,877	572	30.5	1,820	580	31.9	1,769	572	32.3	1,754	498	28.4
Transgender male-to-female^b	25	5	20.0	23	7	30.4	19	4	21.1	15	3	20.0	28	6	21.4
Transgender female-to-male^b	1	0	0.0	1	0	0.0	1	0	0.0	1	0	0.0	0	0	0.0
Additional gender identity^c	0	0	0.0	1	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Age at diagnosis (yr)
50–54	2,991	1,046	35.0	2,847	992	34.8	2,640	926	35.1	2,467	867	35.1	2,301	738	32.1
55–59	1,882	678	36.0	1,881	699	37.2	1,873	657	35.1	1,841	647	35.1	1,827	594	32.5
60–64	995	388	39.0	1,080	369	34.2	1,087	387	35.6	1,040	356	34.2	1,100	383	34.8
65–69	538	211	39.2	563	203	36.1	519	182	35.1	484	177	36.6	501	199	39.7
70–74	197	76	38.6	188	84	44.7	224	73	32.6	248	92	37.1	233	88	37.8
75–79	82	27	32.9	71	31	43.7	90	45	50.0	91	39	42.9	91	34	37.4
80–84	28	11	39.3	27	15	55.6	35	11	31.4	34	10	29.4	32	11	34.4
≥85	6	1	16.7	10	1	10.0	9	2	22.2	13	2	15.4	17	6	35.3
Race/ethnicity
American Indian/Alaska Native	22	9	40.9	30	7	23.3	33	12	36.4	27	11	40.7	29	8	27.6
Asian	104	52	50.0	120	44	36.7	115	53	46.1	113	44	38.9	115	43	37.4
Black/African American	2,733	922	33.7	2,677	885	33.1	2,651	857	32.3	2,494	830	33.3	2,518	792	31.5
Hispanic/Latino^d	1,234	449	36.4	1,260	481	38.2	1,254	467	37.2	1,338	517	38.6	1,254	439	35.0
Native Hawaiian/other Pacific Islander	10	4	40.0	7	1	14.3	4	3	75.0	9	3	33.3	6	3	50.0
White	2,397	915	38.2	2,381	897	37.7	2,267	829	36.6	2,106	735	34.9	2,051	713	34.8
Multiracial	219	87	39.7	192	79	41.1	153	62	40.5	131	50	38.2	129	55	42.6
Transmission Category^e
Male adult^f
Male-to-male sexual contact	3,213	1,148	35.7	3,154	1,165	36.9	3,094	1,089	35.2	2,954	1,037	35.1	2,888	987	34.2
Injection drug use	416	165	39.6	392	146	37.1	380	138	36.4	383	141	36.8	355	130	36.6
Male-to-male sexual contact and injection drug use	180	73	40.3	177	64	35.9	171	47	27.7	147	48	32.6	160	48	30.1
Heterosexual contact^g	1,107	454	41.0	1,053	443	42.0	999	424	42.5	951	387	40.7	929	384	41.4
Other^h	10	3	34.3	11	5	48.2	12	4	33.6	13	5	33.8	15	6	39.2
Subtotal	4,926	1,842	37.4	4,788	1,822	38.1	4,656	1,703	36.6	4,448	1,618	36.4	4,348	1,555	35.8
Female adult^f
Injection drug use	256	89	34.9	276	88	31.8	238	81	34.1	254	89	35.0	241	72	30.0
Heterosexual contact^g	1,532	504	32.9	1,600	483	30.2	1,578	497	31.5	1,511	480	31.8	1,510	425	28.1
Other^h	6	2	38.6	4	2	48.6	4	2	39.5	5	3	52.0	3	1	26.7
Subtotal	1,793	596	33.2	1,879	572	30.4	1,821	580	31.9	1,770	572	32.3	1,754	498	28.4
Region of residenceⁱ
Northeast	1,343	506	37.7	1,239	419	33.8	1,170	426	36.4	1,145	412	36.0	1,037	368	35.5
Midwest	775	297	38.3	811	344	42.4	774	290	37.5	737	285	38.7	703	245	34.9
South	3,373	1,203	35.7	3,352	1,182	35.3	3,297	1,158	35.1	3,167	1,067	33.7	3,225	1,071	33.2
West	1,228	432	35.2	1,265	449	35.5	1,236	409	33.1	1,169	426	36.4	1,137	369	32.5
Total	6,719	2,438	36.3	6,667	2,394	35.9	6,477	2,283	35.2	6,218	2,190	35.2	6,102	2,053	33.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note: Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Hispanic/Latino persons can be of any race.
^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to the column subtotals and total.
^f Data presented based on sex at birth and include transgender persons.
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Includes persons whose infection were attributed to hemophilia, blood transfusion, or whose risk factor was not reported or not identified.
ⁱ Data are based on residence at time of diagnosis of HIV infection.

Table S8b. Stage 3 (AIDS) at the time of diagnosis of HIV infection among adults aged ≥50 years, by year of diagnosis and selected characteristics, 2015-2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender
Male	5,000	1,871	37.4	4,877	1,856	38.1	4,732	1,725	36.5	4,520	1,653	36.6	4,402	1,578	35.8
Female	1,831	608	33.2	1,910	583	30.5	1,852	589	31.8	1,800	583	32.4	1,786	507	28.4
Transgender male-to-female^b	25	5	20.0	23	7	30.4	19	4	21.1	15	3	20.0	28	6	21.4
Transgender female-to-male^b	1	0	0.0	1	0	0.0	1	0	0.0	1	0	0.0	0	0	0.0
Additional gender identity^c	0	0	0.0	1	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Age at diagnosis (yr)
50–54	3,049	1,069	35.1	2,893	1,009	34.9	2,692	942	35.0	2,517	888	35.3	2,329	749	32.2
55–59	1,915	686	35.8	1,930	712	36.9	1,907	668	35.0	1,868	659	35.3	1,863	602	32.3
60–64	1,010	390	38.6	1,105	378	34.2	1,108	391	35.3	1,060	364	34.3	1,123	389	34.6
65–69	560	220	39.3	580	213	36.7	526	184	35.0	496	181	36.5	516	206	39.9
70–74	205	78	38.0	192	85	44.3	230	74	32.2	254	94	37.0	243	94	38.7
75–79	84	29	34.5	73	33	45.2	94	45	47.9	93	40	43.0	93	34	36.6
80–84	28	11	39.3	28	15	53.6	37	12	32.4	34	10	29.4	32	11	34.4
≥85	6	1	16.7	11	1	9.1	10	2	20.0	14	3	21.4	17	6	35.3
Race/ethnicity
American Indian/Alaska Native	22	9	40.9	30	7	23.3	33	12	36.4	27	11	40.7	29	8	27.6
Asian	104	52	50.0	120	44	36.7	115	53	46.1	113	44	38.9	115	43	37.4
Black/African American	2,735	923	33.7	2,679	886	33.1	2,651	857	32.3	2,495	830	33.3	2,521	793	31.5
Hispanic/Latino^d	1,367	491	35.9	1,402	531	37.9	1,377	500	36.3	1,451	564	38.9	1,363	476	34.9
Native Hawaiian/other Pacific Islander	11	5	45.5	8	2	25.0	6	5	83.3	10	4	40.0	7	3	42.9
White	2,399	917	38.2	2,381	897	37.7	2,269	829	36.5	2,108	736	34.9	2,052	713	34.7
Multiracial	219	87	39.7	192	79	41.1	153	62	40.5	132	50	37.9	129	55	42.6
Transmission Category^e
Male adult^f
Male-to-male sexual contact	3,254	1,163	35.7	3,200	1,174	36.7	3,134	1,104	35.2	2,994	1,052	35.1	2,925	998	34.1
Injection drug use	437	168	38.5	410	154	37.6	401	144	36.0	394	146	37.0	366	134	36.8
Male-to-male sexual contact and injection drug use	185	75	40.6	177	64	35.9	171	47	27.7	150	50	33.4	162	49	30.4
Heterosexual contact^g	1,140	467	41.0	1,102	466	42.3	1,033	429	41.6	984	404	41.0	962	396	41.2
Other^h	10	4	35.0	11	5	48.2	12	4	33.1	13	5	33.8	15	6	39.2
Subtotal	5,025	1,876	37.3	4,900	1,863	38.0	4,751	1,729	36.4	4,535	1,656	36.5	4,430	1,584	35.8
Female adult^f
Injection drug use	257	89	34.8	279	89	31.8	242	81	33.7	254	89	35.0	243	73	30.1
Heterosexual contact^g	1,569	516	32.9	1,629	492	30.2	1,607	506	31.5	1,542	491	31.9	1,540	433	28.1
Other^h	6	2	38.6	4	2	47.2	4	2	39.5	5	3	52.0	3	1	26.7
Subtotal	1,832	608	33.2	1,912	583	30.5	1,853	589	31.8	1,801	583	32.4	1,786	507	28.4
Region of residenceⁱ
Northeast	1,343	506	37.7	1,239	419	33.8	1,170	426	36.4	1,145	412	36.0	1,037	368	35.5
Midwest	775	297	38.3	811	344	42.4	774	290	37.5	737	285	38.7	703	245	34.9
South	3,373	1,203	35.7	3,352	1,182	35.3	3,297	1,158	35.1	3,167	1,067	33.7	3,225	1,071	33.2
West	1,228	432	35.2	1,265	449	35.5	1,236	409	33.1	1,169	426	36.4	1,137	369	32.5
U.S. dependent areas	138	46	33.3	145	52	35.9	127	35	27.6	118	49	41.5	114	38	33.3
Total	6,857	2,484	36.2	6,812	2,446	35.9	6,604	2,318	35.1	6,336	2,239	35.3	6,216	2,091	33.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note: Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Hispanic/Latino persons can be of any race.
^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to the column subtotals and total.
^f Data presented based on sex at birth and include transgender persons.
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Includes persons whose infection were attributed to hemophilia, blood transfusion, or whose risk factor was not reported or not identified.
ⁱ Data are based on residence at time of diagnosis of HIV infection.

Table S9a. Stage 3 (AIDS) at the time of diagnosis of HIV infection among adults aged ≥50 years, by year of diagnosis, sex at birth, and selected characteristics, 2015–2019—United States
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Male adult
Age at diagnosis (yr)
50–54	2,252	819	36.4	2,123	781	36.8	1,980	702	35.5	1,808	656	36.3	1,677	584	34.8
55–59	1,348	499	37.0	1,308	519	39.7	1,313	490	37.3	1,297	477	36.8	1,317	448	34.0
60–64	700	285	40.7	734	272	37.1	755	282	37.4	720	256	35.6	748	286	38.2
65–69	386	154	39.9	407	152	37.3	368	140	38.0	350	137	39.1	344	140	40.7
70–74	154	58	37.7	141	66	46.8	152	50	32.9	177	62	35.0	160	59	36.9
75–79	64	22	34.4	54	21	38.9	55	28	50.9	62	25	40.3	67	25	37.3
80–84	16	4	25.0	17	10	58.8	27	10	37.0	25	5	20.0	24	10	41.7
≥85	6	1	16.7	4	1	25.0	6	1	16.7	9	0	0.0	11	3	27.3
Race/ethnicity
American Indian/Alaska Native	14	4	28.6	20	6	30.0	21	7	33.3	20	9	45.0	21	6	28.6
Asian	81	45	55.6	93	34	36.6	84	43	51.2	85	33	38.8	91	37	40.7
Black/African American	1,652	585	35.4	1,556	572	36.8	1,546	536	34.7	1,467	526	35.9	1,460	512	35.1
Hispanic/Latino^b	946	354	37.4	946	373	39.4	967	373	38.6	995	390	39.2	963	344	35.7
Native Hawaiian/other Pacific Islander	8	4	50.0	4	0	0.0	3	2	66.7	7	3	42.9	5	2	40.0
White	2,069	785	37.9	2,032	779	38.3	1,919	698	36.4	1,788	624	34.9	1,720	612	35.6
Multiracial	156	65	41.7	137	58	42.3	116	44	37.9	86	33	38.4	88	42	47.7
Region of residence^c
Northeast	926	367	39.6	826	308	37.3	767	293	38.2	771	289	37.5	689	261	37.9
Midwest	595	245	41.2	623	276	44.3	585	226	38.6	576	229	39.8	526	192	36.5
South	2,392	877	36.7	2,316	855	36.9	2,294	840	36.6	2,189	772	35.3	2,222	793	35.7
West	1,013	353	34.8	1,023	383	37.4	1,010	344	34.1	912	328	36.0	911	309	33.9
Subtotal, male adult	4,926	1,842	37.4	4,788	1,822	38.1	4,656	1,703	36.6	4,448	1,618	36.4	4,348	1,555	35.8
Female adult
Age at diagnosis (yr)
50–54	739	227	30.7	724	211	29.1	660	224	33.9	659	211	32.0	624	154	24.7
55–59	534	179	33.5	573	180	31.4	560	167	29.8	544	170	31.3	510	146	28.6
60–64	295	103	34.9	346	97	28.0	332	105	31.6	320	100	31.3	352	97	27.6
65–69	152	57	37.5	156	51	32.7	151	42	27.8	134	40	29.9	157	59	37.6
70–74	43	18	41.9	47	18	38.3	72	23	31.9	71	30	42.3	73	29	39.7
75–79	18	5	27.8	17	10	58.8	35	17	48.6	29	14	48.3	24	9	37.5
80–84	12	7	58.3	10	5	50.0	8	1	12.5	9	5	55.6	8	1	12.5
≥85	0	0	0.0	6	0	0.0	3	1	33.3	4	2	50.0	6	3	50.0
Race/ethnicity
American Indian/Alaska Native	8	5	62.5	10	1	10.0	12	5	41.7	7	2	28.6	8	2	25.0
Asian	23	7	30.4	27	10	37.0	31	10	32.3	28	11	39.3	24	6	25.0
Black/African American	1,081	337	31.2	1,121	313	27.9	1,105	321	29.0	1,027	304	29.6	1,058	280	26.5
Hispanic/Latino^b	288	95	33.0	314	108	34.4	287	94	32.8	343	127	37.0	291	95	32.6
Native Hawaiian/other Pacific Islander	2	0	0.0	3	1	33.3	1	1	100	2	0	0.0	1	1	100
White	328	130	39.6	349	118	33.8	348	131	37.6	318	111	34.9	331	101	30.5
Multiracial	63	22	34.9	55	21	38.2	37	18	48.6	45	17	37.8	41	13	31.7
Region of residence^c
Northeast	417	139	33.3	413	111	26.9	403	133	33.0	374	123	32.9	348	107	30.7
Midwest	180	52	28.9	188	68	36.2	189	64	33.9	161	56	34.8	177	53	29.9
South	981	326	33.2	1,036	327	31.6	1,003	318	31.7	978	295	30.2	1,003	278	27.7
West	215	79	36.7	242	66	27.3	226	65	28.8	257	98	38.1	226	60	26.5
Subtotal, female adult	1,793	596	33.2	1,879	572	30.4	1,821	580	31.9	1,770	572	32.3	1,754	498	28.4
Total	6,719	2,438	36.3	6,667	2,394	35.9	6,477	2,283	35.2	6,218	2,190	35.2	6,102	2,053	33.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note: Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b Hispanic/Latino persons can be of any race.
^c Data are based on residence at time of diagnosis of HIV infection.

Table S9b. Stage 3 (AIDS) at the time of diagnosis of HIV infection among adults aged ≥50 years, by year of diagnosis, sex at birth, and selected characteristics, 2015–2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Male adult
Age at diagnosis (yr)
50–54	2,296	838	36.5	2,160	794	36.8	2,020	715	35.4	1,846	672	36.4	1,699	594	35.0
55–59	1,369	504	36.8	1,343	528	39.3	1,336	497	37.2	1,316	485	36.9	1,340	454	33.9
60–64	714	287	40.2	752	279	37.1	771	286	37.1	735	263	35.8	766	291	38.0
65–69	398	158	39.7	422	161	38.2	374	141	37.7	359	141	39.3	355	145	40.8
70–74	160	60	37.5	145	67	46.2	155	50	32.3	181	63	34.8	166	62	37.3
75–79	66	24	36.4	56	23	41.1	59	28	47.5	63	26	41.3	69	25	36.2
80–84	16	4	25.0	18	10	55.6	29	11	37.9	25	5	20.0	24	10	41.7
≥85	6	1	16.7	4	1	25.0	7	1	14.3	10	1	10.0	11	3	27.3
Race/ethnicity
American Indian/Alaska Native	14	4	28.6	20	6	30.0	21	7	33.3	20	9	45.0	21	6	28.6
Asian	81	45	55.6	93	34	36.6	84	43	51.2	85	33	38.8	91	37	40.7
Black/African American	1,652	585	35.4	1,558	573	36.8	1,546	536	34.7	1,468	526	35.8	1,462	513	35.1
Hispanic/Latino^b	1,042	385	36.9	1,055	412	39.1	1,059	397	37.5	1,077	426	39.6	1,041	372	35.7
Native Hawaiian/other Pacific Islander	9	5	55.6	5	1	20.0	5	4	80.0	8	4	50.0	6	2	33.3
White	2,071	787	38.0	2,032	779	38.3	1,920	698	36.4	1,790	625	34.9	1,721	612	35.6
Multiracial	156	65	41.7	137	58	42.3	116	44	37.9	87	33	37.9	88	42	47.7
Region of residence^c
Northeast	926	367	39.6	826	308	37.3	767	293	38.2	771	289	37.5	689	261	37.9
Midwest	595	245	41.2	623	276	44.3	585	226	38.6	576	229	39.8	526	192	36.5
South	2,392	877	36.7	2,316	855	36.9	2,294	840	36.6	2,189	772	35.3	2,222	793	35.7
West	1,013	353	34.8	1,023	383	37.4	1,010	344	34.1	912	328	36.0	911	309	33.9
U.S. dependent areas	99	34	34.3	112	41	36.6	95	26	27.4	87	38	43.7	82	29	35.4
Subtotal, male adult	5,025	1,876	37.3	4,900	1,863	38.0	4,751	1,729	36.4	4,535	1,656	36.5	4,430	1,584	35.8
Female adult
Age at diagnosis (yr)
50–54	753	231	30.7	733	215	29.3	672	227	33.8	671	216	32.2	630	155	24.6
55–59	546	182	33.3	587	184	31.3	571	171	29.9	552	174	31.5	523	148	28.3
60–64	296	103	34.8	353	99	28.0	337	105	31.2	325	101	31.1	357	98	27.5
65–69	162	62	38.3	158	52	32.9	152	43	28.3	137	40	29.2	161	61	37.9
70–74	45	18	40.0	47	18	38.3	75	24	32.0	73	31	42.5	77	32	41.6
75–79	18	5	27.8	17	10	58.8	35	17	48.6	30	14	46.7	24	9	37.5
80–84	12	7	58.3	10	5	50.0	8	1	12.5	9	5	55.6	8	1	12.5
≥85	0	0	0.0	7	0	0.0	3	1	33.3	4	2	50.0	6	3	50.0
Race/ethnicity
American Indian/Alaska Native	8	5	62.5	10	1	10.0	12	5	41.7	7	2	28.6	8	2	25.0
Asian	23	7	30.4	27	10	37.0	31	10	32.3	28	11	39.3	24	6	25.0
Black/African American	1,083	338	31.2	1,121	313	27.9	1,105	321	29.0	1,027	304	29.6	1,059	280	26.4
Hispanic/Latino^b	325	106	32.6	347	119	34.3	318	103	32.4	374	138	36.9	322	104	32.3
Native Hawaiian/other Pacific Islander	2	0	0.0	3	1	33.3	1	1	100	2	0	0.0	1	1	100
White	328	130	39.6	349	118	33.8	349	131	37.5	318	111	34.9	331	101	30.5
Multiracial	63	22	34.9	55	21	38.2	37	18	48.6	45	17	37.8	41	13	31.7
Region of residence^c
Northeast	417	139	33.3	413	111	26.9	403	133	33.0	374	123	32.9	348	107	30.7
Midwest	180	52	28.9	188	68	36.2	189	64	33.9	161	56	34.8	177	53	29.9
South	981	326	33.2	1,036	327	31.6	1,003	318	31.7	978	295	30.2	1,003	278	27.7
West	215	79	36.7	242	66	27.3	226	65	28.8	257	98	38.1	226	60	26.5
U.S. dependent areas	39	12	30.8	33	11	33.3	32	9	28.1	31	11	35.5	32	9	28.1
Subtotal, female adult	1,832	608	33.2	1,912	583	30.5	1,853	589	31.8	1,801	583	32.4	1,786	507	28.4
Total	6,857	2,484	36.2	6,812	2,446	35.9	6,604	2,318	35.1	6,336	2,239	35.3	6,216	2,091	33.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note: Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b Hispanic/Latino persons can be of any race.
^c Data are based on residence at time of diagnosis of HIV infection.

Table S10a. Stage 3 (AIDS) at the time of diagnosis of HIV infection among adults aged ≥50 years, by year of diagnosis, age group, sex at birth, and selected characteristics, 2015–2019—United States
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Aged 50–64 years at diagnosis
Male adult
Race/Ethnicity
American Indian/Alaska Native	14	4	28.6	17	4	23.5	18	6	33.3	17	8	47.1	20	5	25.0
Asian	71	40	56.3	74	26	35.1	73	39	53.4	69	27	39.1	78	32	41.0
Black/African American	1,432	501	35.0	1,335	483	36.2	1,330	462	34.7	1,243	446	35.9	1,220	418	34.3
Hispanic/Latino^b	833	313	37.6	851	324	38.1	848	333	39.3	885	347	39.2	853	295	34.6
Native Hawaiian/other Pacific Islander	8	4	50.0	2	0	0.0	2	1	50.0	6	2	33.3	5	2	40.0
White	1,812	687	37.9	1,762	680	38.6	1,673	596	35.6	1,533	531	34.6	1,492	530	35.5
Multiracial	130	54	41.5	124	55	44.4	104	37	35.6	72	28	38.9	74	36	48.6
Transmission category^c
Male-to-male sexual contact	2,864	1,021	35.6	2,814	1,034	36.8	2,758	966	35.0	2,576	903	35.1	2,545	858	33.7
Injection drug use	357	141	39.6	330	122	37.0	316	115	36.5	333	122	36.4	302	107	35.5
Male-to-male sexual contact and injection drug use	170	67	39.2	159	56	35.1	155	41	26.4	136	45	33.1	143	42	29.2
Heterosexual contact^d	905	373	41.2	857	357	41.7	813	350	43.1	773	317	41.0	745	308	41.4
Other^e	4	2	37.5	5	3	48.1	6	2	36.1	8	3	33.3	8	3	39.3
Region of residence^f
Northeast	792	314	39.6	701	255	36.4	655	243	37.1	658	242	36.8	579	220	38.0
Midwest	532	215	40.4	567	252	44.4	512	192	37.5	499	194	38.9	450	159	35.3
South	2,077	763	36.7	2,000	734	36.7	1,986	731	36.8	1,886	672	35.6	1,906	677	35.5
West	899	311	34.6	897	331	36.9	895	308	34.4	782	281	35.9	807	262	32.5
Subtotal, male adult aged 50–64 years	4,300	1,603	37.3	4,165	1,572	37.7	4,048	1,474	36.4	3,825	1,389	36.3	3,742	1,318	35.2
Female adult
Race/Ethnicity
American Indian/Alaska Native	7	5	71.4	9	1	11.1	11	5	45.5	7	2	28.6	6	0	0.0
Asian	18	5	27.8	22	10	45.5	26	10	38.5	22	9	40.9	19	4	21.1
Black/African American	933	282	30.2	981	271	27.6	918	262	28.5	881	256	29.1	877	220	25.1
Hispanic/Latino^b	252	82	32.5	266	84	31.6	246	82	33.3	292	106	36.3	243	73	30.0
Native Hawaiian/other Pacific Islander	2	0	0.0	3	1	33.3	1	1	100	2	0	0.0	1	1	100
White	297	116	39.1	317	106	33.4	318	120	37.7	284	94	33.1	306	90	29.4
Multiracial	59	19	32.2	45	15	33.3	32	16	50.0	35	14	40.0	34	9	26.5
Transmission category^c
Injection drug use	229	80	34.8	244	75	30.8	211	74	35.2	225	74	32.7	209	56	26.9
Heterosexual contact^d	1,336	428	32.1	1,397	412	29.5	1,339	421	31.5	1,296	406	31.4	1,275	340	26.7
Other^e	3	1	37.0	2	1	50.0	2	1	33.3	2	1	47.8	2	1	36.8
Region of residence^f
Northeast	362	114	31.5	354	87	24.6	342	115	33.6	318	104	32.7	286	82	28.7
Midwest	159	46	28.9	173	65	37.6	169	58	34.3	140	49	35.0	157	42	26.8
South	862	281	32.6	901	276	30.6	837	264	31.5	850	248	29.2	854	227	26.6
West	185	68	36.8	215	60	27.9	204	59	28.9	215	80	37.2	189	46	24.3
Subtotal, female adult aged 50–64 years	1,568	509	32.5	1,643	488	29.7	1,552	496	32.0	1,523	481	31.6	1,486	397	26.7
Both sexes
Race/Ethnicity
American Indian/Alaska Native	21	9	42.9	26	5	19.2	29	11	37.9	24	10	41.7	26	5	19.2
Asian	89	45	50.6	96	36	37.5	99	49	49.5	91	36	39.6	97	36	37.1
Black/African American	2,365	783	33.1	2,316	754	32.6	2,248	724	32.2	2,124	702	33.1	2,097	638	30.4
Hispanic/Latino^b	1,085	395	36.4	1,117	408	36.5	1,094	415	37.9	1,177	453	38.5	1,096	368	33.6
Native Hawaiian/other Pacific Islander	10	4	40.0	5	1	20.0	3	2	66.7	8	2	25.0	6	3	50.0
White	2,109	803	38.1	2,079	786	37.8	1,991	716	36.0	1,817	625	34.4	1,798	620	34.5
Multiracial	189	73	38.6	169	70	41.4	136	53	39.0	107	42	39.3	108	45	41.7
Region of residence^f
Northeast	1,154	428	37.1	1,055	342	32.4	997	358	35.9	976	346	35.5	865	302	34.9
Midwest	691	261	37.8	740	317	42.8	681	250	36.7	639	243	38.0	607	201	33.1
South	2,939	1,044	35.5	2,901	1,010	34.8	2,823	995	35.2	2,736	920	33.6	2,760	904	32.8
West	1,084	379	35.0	1,112	391	35.2	1,099	367	33.4	997	361	36.2	996	308	30.9
Subtotal, aged 50–64 years at diagnosis	5,868	2,112	36.0	5,808	2,060	35.5	5,600	1,970	35.2	5,348	1,870	35.0	5,228	1,715	32.8
Aged ≥65 years at diagnosis
Male adult
Race/Ethnicity
American Indian/Alaska Native	0	0	0.0	3	2	66.7	3	1	33.3	3	1	33.3	1	1	100
Asian	10	5	50.0	19	8	42.1	11	4	36.4	16	6	37.5	13	5	38.5
Black/African American	220	84	38.2	221	89	40.3	216	74	34.3	224	80	35.7	240	94	39.2
Hispanic/Latino^b	113	41	36.3	95	49	51.6	119	40	33.6	110	43	39.1	110	49	44.5
Native Hawaiian/other Pacific Islander	0	0	0.0	2	0	0.0	1	1	100	1	1	100	0	0	0.0
White	257	98	38.1	270	99	36.7	246	102	41.5	255	93	36.5	228	82	36.0
Multiracial	26	11	42.3	13	3	23.1	12	7	58.3	14	5	35.7	14	6	42.9
Transmission category^c
Male-to-male sexual contact	349	127	36.4	340	130	38.2	336	123	36.7	378	134	35.5	344	129	37.5
Injection drug use	59	23	39.8	63	24	37.6	64	23	36.3	50	19	39.0	54	23	42.4
Male-to-male sexual contact and injection drug use	10	6	57.8	18	8	43.5	16	7	39.9	12	3	27.0	17	7	38.2
Heterosexual contact^d	202	81	40.0	196	86	43.6	186	74	39.9	179	70	39.4	185	76	41.2
Other^e	6	2	32.2	6	3	48.3	6	2	30.9	6	2	34.5	7	3	39.1
Region of residence^f
Northeast	134	53	39.6	125	53	42.4	112	50	44.6	113	47	41.6	110	41	37.3
Midwest	63	30	47.6	56	24	42.9	73	34	46.6	77	35	45.5	76	33	43.4
South	315	114	36.2	316	121	38.3	308	109	35.4	303	100	33.0	316	116	36.7
West	114	42	36.8	126	52	41.3	115	36	31.3	130	47	36.2	104	47	45.2
Subtotal, male adult aged ≥65 years	626	239	38.2	623	250	40.1	608	229	37.7	623	229	36.8	606	237	39.1
Female adult
Race/Ethnicity
American Indian/Alaska Native	1	0	0.0	1	0	0.0	1	0	0.0	0	0	0.0	2	2	100
Asian	5	2	40.0	5	0	0.0	5	0	0.0	6	2	33.3	5	2	40.0
Black/African American	148	55	37.2	140	42	30.0	187	59	31.6	146	48	32.9	181	60	33.1
Hispanic/Latino^b	36	13	36.1	48	24	50.0	41	12	29.3	51	21	41.2	48	22	45.8
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
White	31	14	45.2	32	12	37.5	30	11	36.7	34	17	50.0	25	11	44.0
Multiracial	4	3	75.0	10	6	60.0	5	2	40.0	10	3	30.0	7	4	57.1
Transmission category^c
Injection drug use	26	10	36.0	32	13	39.7	28	7	26.3	29	16	53.2	32	16	50
Heterosexual contact^d	196	76	39.0	203	71	34.9	239	76	31.7	215	74	34.4	235	85	36.2
Other^e	3	1	40.0	2	1	46.7	2	1	47.4	3	2	55.6	1	0	9.1
Region of residence^f
Northeast	55	25	45.5	59	24	40.7	61	18	29.5	56	19	33.9	62	25	40.3
Midwest	21	6	28.6	15	3	20.0	20	6	30.0	21	7	33.3	20	11	55.0
South	119	45	37.8	135	51	37.8	166	54	32.5	128	47	36.7	149	51	34.2
West	30	11	36.7	27	6	22.2	22	6	27.3	42	18	42.9	37	14	37.8
Subtotal, female adult aged ≥65 years	225	87	38.7	236	84	35.6	269	84	31.2	247	91	36.8	268	101	37.7
Both sexes
Race/Ethnicity
American Indian/Alaska Native	1	0	0.0	4	2	50.0	4	1	25.0	3	1	33.3	3	3	100
Asian	15	7	46.7	24	8	33.3	16	4	25.0	22	8	36.4	18	7	38.9
Black/African American	368	139	37.8	361	131	36.3	403	133	33.0	370	128	34.6	421	154	36.6
Hispanic/Latino^b	149	54	36.2	143	73	51.0	160	52	32.5	161	64	39.8	158	71	44.9
Native Hawaiian/other Pacific Islander	0	0	0.0	2	0	0.0	1	1	100	1	1	100	0	0	0.0
White	288	112	38.9	302	111	36.8	276	113	40.9	289	110	38.1	253	93	36.8
Multiracial	30	14	46.7	23	9	39.1	17	9	52.9	24	8	33.3	21	10	47.6
Region of residence^f
Northeast	189	78	41.3	184	77	41.8	173	68	39.3	169	66	39.1	172	66	38.4
Midwest	84	36	42.9	71	27	38.0	93	40	43.0	98	42	42.9	96	44	45.8
South	434	159	36.6	451	172	38.1	474	163	34.4	431	147	34.1	465	167	35.9
West	144	53	36.8	153	58	37.9	137	42	30.7	172	65	37.8	141	61	43.3
Subtotal, aged ≥65 years at diagnosis	851	326	38.3	859	334	38.9	877	313	35.7	870	320	36.8	874	338	38.7
Total	6,719	2,438	36.3	6,667	2,394	35.9	6,477	2,283	35.2	6,218	2,190	35.2	6,102	2,053	33.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note: Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b Hispanic/Latino persons can be of any race.
^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to the column subtotals and total.
^d Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^e Includes persons whose infection were attributed to hemophilia, blood transfusion, or whose risk factor was not reported or not identified.
^f Data are based on residence at time of diagnosis of HIV infection.

Table S10b. Stage 3 (AIDS) at the time of diagnosis of HIV infection among adults aged ≥50 years, by year of diagnosis, age group, sex at birth, and selected characteristics, 2015–2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Aged 50–64 years at diagnosis
Male adult
Race/Ethnicity
American Indian/Alaska Native	14	4	28.6	17	4	23.5	18	6	33.3	17	8	47.1	20	5	25.0
Asian	71	40	56.3	74	26	35.1	73	39	53.4	69	27	39.1	78	32	41.0
Black/African American	1,432	501	35.0	1,337	484	36.2	1,330	462	34.7	1,244	446	35.9	1,221	418	34.2
Hispanic/Latino^b	909	336	37.0	938	351	37.4	924	355	38.4	952	376	39.5	914	316	34.6
Native Hawaiian/other Pacific Islander	9	5	55.6	3	1	33.3	4	3	75.0	7	3	42.9	6	2	33.3
White	1,814	689	38.0	1,762	680	38.6	1,674	596	35.6	1,535	532	34.7	1,492	530	35.5
Multiracial	130	54	41.5	124	55	44.4	104	37	35.6	73	28	38.4	74	36	48.6
Transmission category^c
Male-to-male sexual contact	2,898	1,033	35.7	2,857	1,043	36.5	2,796	981	35.1	2,614	917	35.1	2,578	869	33.7
Injection drug use	376	145	38.5	344	128	37.2	333	121	36.4	342	126	36.8	309	110	35.8
Male-to-male sexual contact and injection drug use	173	68	39.5	159	56	35.1	155	41	26.4	138	46	33.4	144	42	29.0
Heterosexual contact^d	928	381	41.0	889	371	41.8	836	353	42.2	796	329	41.3	766	315	41.1
Other^e	4	2	39.0	5	3	48.1	6	2	35.5	8	3	33.3	8	3	39.3
Region of residence^f
Northeast	792	314	39.6	701	255	36.4	655	243	37.1	658	242	36.8	579	220	38.0
Midwest	532	215	40.4	567	252	44.4	512	192	37.5	499	194	38.9	450	159	35.3
South	2,077	763	36.7	2,000	734	36.7	1,986	731	36.8	1,886	672	35.6	1,906	677	35.5
West	899	311	34.6	897	331	36.9	895	308	34.4	782	281	35.9	807	262	32.5
U.S. dependent areas	79	26	32.9	90	29	32.2	79	24	30.4	72	31	43.1	63	21	33.3
Subtotal, male adult aged 50–64 years	4,379	1,629	37.2	4,255	1,601	37.6	4,127	1,498	36.3	3,897	1,420	36.4	3,805	1,339	35.2
Female adult
Race/Ethnicity
American Indian/Alaska Native	7	5	71.4	9	1	11.1	11	5	45.5	7	2	28.6	6	0	0.0
Asian	18	5	27.8	22	10	45.5	26	10	38.5	22	9	40.9	19	4	21.1
Black/African American	933	282	30.2	981	271	27.6	918	262	28.5	881	256	29.1	878	220	25.1
Hispanic/Latino^b	279	89	31.9	296	94	31.8	273	89	32.6	317	116	36.6	266	77	28.9
Native Hawaiian/other Pacific Islander	2	0	0.0	3	1	33.3	1	1	100	2	0	0.0	1	1	100
White	297	116	39.1	317	106	33.4	319	120	37.6	284	94	33.1	306	90	29.4
Multiracial	59	19	32.2	45	15	33.3	32	16	50.0	35	14	40.0	34	9	26.5
Transmission category^c
Injection drug use	230	80	34.6	247	76	30.8	214	74	34.7	225	74	32.6	211	57	27.2
Heterosexual contact^d	1,362	435	32.0	1,424	421	29.6	1,364	428	31.4	1,321	416	31.5	1,297	343	26.4
Other^e	3	1	37.0	2	1	50.0	2	1	33.3	2	1	47.8	2	1	36.8
Region of residence^f
Northeast	362	114	31.5	354	87	24.6	342	115	33.6	318	104	32.7	286	82	28.7
Midwest	159	46	28.9	173	65	37.6	169	58	34.3	140	49	35.0	157	42	26.8
South	862	281	32.6	901	276	30.6	837	264	31.5	850	248	29.2	854	227	26.6
West	185	68	36.8	215	60	27.9	204	59	28.9	215	80	37.2	189	46	24.3
U.S. dependent areas	27	7	25.9	30	10	33.3	28	7	25.0	25	10	40.0	24	4	16.7
Subtotal, female adult aged 50–64 years	1,595	516	32.4	1,673	498	29.8	1,580	503	31.8	1,548	491	31.7	1,510	401	26.6
Both sexes
Race/Ethnicity
American Indian/Alaska Native	21	9	42.9	26	5	19.2	29	11	37.9	24	10	41.7	26	5	19.2
Asian	89	45	50.6	96	36	37.5	99	49	49.5	91	36	39.6	97	36	37.1
Black/African American	2,365	783	33.1	2,318	755	32.6	2,248	724	32.2	2,125	702	33.0	2,099	638	30.4
Hispanic/Latino^b	1,188	425	35.8	1,234	445	36.1	1,197	444	37.1	1,269	492	38.8	1,180	393	33.3
Native Hawaiian/other Pacific Islander	11	5	45.5	6	2	33.3	5	4	80.0	9	3	33.3	7	3	42.9
White	2,111	805	38.1	2,079	786	37.8	1,993	716	35.9	1,819	626	34.4	1,798	620	34.5
Multiracial	189	73	38.6	169	70	41.4	136	53	39.0	108	42	38.9	108	45	41.7
Region of residence^f
Northeast	1,154	428	37.1	1,055	342	32.4	997	358	35.9	976	346	35.5	865	302	34.9
Midwest	691	261	37.8	740	317	42.8	681	250	36.7	639	243	38.0	607	201	33.1
South	2,939	1,044	35.5	2,901	1,010	34.8	2,823	995	35.2	2,736	920	33.6	2,760	904	32.8
West	1,084	379	35.0	1,112	391	35.2	1,099	367	33.4	997	361	36.2	996	308	30.9
U.S. dependent areas	106	33	31.1	120	39	32.5	107	31	29.0	97	41	42.3	87	25	28.7
Subtotal, aged 50–64 years at diagnosis	5,974	2,145	35.9	5,928	2,099	35.4	5,707	2,001	35.1	5,445	1,911	35.1	5,315	1,740	32.7
Aged ≥65 years at diagnosis
Male adult
Race/Ethnicity
American Indian/Alaska Native	0	0	0.0	3	2	66.7	3	1	33.3	3	1	33.3	1	1	100
Asian	10	5	50.0	19	8	42.1	11	4	36.4	16	6	37.5	13	5	38.5
Black/African American	220	84	38.2	221	89	40.3	216	74	34.3	224	80	35.7	241	95	39.4
Hispanic/Latino^b	133	49	36.8	117	61	52.1	135	42	31.1	125	50	40.0	127	56	44.1
Native Hawaiian/other Pacific Islander	0	0	0.0	2	0	0.0	1	1	100	1	1	100	0	0	0.0
White	257	98	38.1	270	99	36.7	246	102	41.5	255	93	36.5	229	82	35.8
Multiracial	26	11	42.3	13	3	23.1	12	7	58.3	14	5	35.7	14	6	42.9
Transmission category^c
Male-to-male sexual contact	356	129	36.3	343	130	38.1	338	123	36.5	380	135	35.6	347	129	37.2
Injection drug use	61	23	38.4	65	26	39.4	68	23	34.2	52	20	38.2	57	24	42.0
Male-to-male sexual contact and injection drug use	12	7	56.6	18	8	43.5	16	7	39.9	13	4	33.3	18	8	41.7
Heterosexual contact^d	212	86	40.6	213	95	44.7	197	76	38.9	188	75	39.8	195	82	41.8
Other^e	6	2	32.2	6	3	48.3	6	2	30.4	6	2	34.5	7	3	39.1
Region of residence^f
Northeast	134	53	39.6	125	53	42.4	112	50	44.6	113	47	41.6	110	41	37.3
Midwest	63	30	47.6	56	24	42.9	73	34	46.6	77	35	45.5	76	33	43.4
South	315	114	36.2	316	121	38.3	308	109	35.4	303	100	33.0	316	116	36.7
West	114	42	36.8	126	52	41.3	115	36	31.3	130	47	36.2	104	47	45.2
U.S. dependent areas	20	8	40.0	22	12	54.5	16	2	12.5	15	7	46.7	19	8	42.1
Subtotal, male adult aged ≥65 years	646	247	38.2	645	262	40.6	624	231	37.0	638	236	37.0	625	245	39.2
Female adult
Race/Ethnicity
American Indian/Alaska Native	1	0	0.0	1	0	0.0	1	0	0.0	0	0	0.0	2	2	100
Asian	5	2	40.0	5	0	0.0	5	0	0.0	6	2	33.3	5	2	40.0
Black/African American	150	56	37.3	140	42	30.0	187	59	31.6	146	48	32.9	181	60	33.1
Hispanic/Latino^b	46	17	37.0	51	25	49.0	45	14	31.1	57	22	38.6	56	27	48.2
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
White	31	14	45.2	32	12	37.5	30	11	36.7	34	17	50.0	25	11	44.0
Multiracial	4	3	75.0	10	6	60.0	5	2	40.0	10	3	30.0	7	4	57.1
Transmission category^c
Injection drug use	27	10	36.2	32	13	39.8	28	7	26.0	29	16	53.2	32	16	49.8
Heterosexual contact^d	208	81	39.1	205	72	34.8	243	78	32.0	221	75	33.9	243	90	37.0
Other^e	3	1	40.0	2	1	43.7	2	1	47.4	3	2	55.6	1	0	9.1
Region of residence^f
Northeast	55	25	45.5	59	24	40.7	61	18	29.5	56	19	33.9	62	25	40.3
Midwest	21	6	28.6	15	3	20.0	20	6	30.0	21	7	33.3	20	11	55.0
South	119	45	37.8	135	51	37.8	166	54	32.5	128	47	36.7	149	51	34.2
West	30	11	36.7	27	6	22.2	22	6	27.3	42	18	42.9	37	14	37.8
U.S. dependent areas	12	5	41.7	3	1	33.3	4	2	50.0	6	1	16.7	8	5	62.5
Subtotal, female adult aged ≥65 years	237	92	38.8	239	85	35.6	273	86	31.5	253	92	36.4	276	106	38.4
Both sexes
Race/Ethnicity
American Indian/Alaska Native	1	0	0.0	4	2	50.0	4	1	25.0	3	1	33.3	3	3	100
Asian	15	7	46.7	24	8	33.3	16	4	25.0	22	8	36.4	18	7	38.9
Black/African American	370	140	37.8	361	131	36.3	403	133	33.0	370	128	34.6	422	155	36.7
Hispanic/Latino^b	179	66	36.9	168	86	51.2	180	56	31.1	182	72	39.6	183	83	45.4
Native Hawaiian/other Pacific Islander	0	0	0.0	2	0	0.0	1	1	100	1	1	100	0	0	0.0
White	288	112	38.9	302	111	36.8	276	113	40.9	289	110	38.1	254	93	36.6
Multiracial	30	14	46.7	23	9	39.1	17	9	52.9	24	8	33.3	21	10	47.6
Region of residence^f
Northeast	189	78	41.3	184	77	41.8	173	68	39.3	169	66	39.1	172	66	38.4
Midwest	84	36	42.9	71	27	38.0	93	40	43.0	98	42	42.9	96	44	45.8
South	434	159	36.6	451	172	38.1	474	163	34.4	431	147	34.1	465	167	35.9
West	144	53	36.8	153	58	37.9	137	42	30.7	172	65	37.8	141	61	43.3
U.S. dependent areas	32	13	40.6	25	13	52.0	20	4	20.0	21	8	38.1	27	13	48.1
Subtotal, aged ≥65 years at diagnosis	883	339	38.4	884	347	39.3	897	317	35.3	891	328	36.8	901	351	39.0
Total	6,857	2,484	36.2	6,812	2,446	35.9	6,604	2,318	35.1	6,336	2,239	35.3	6,216	2,091	33.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note: Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b Hispanic/Latino persons can be of any race.
^c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to the column subtotals and total.
^d Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^e Includes persons whose infection were attributed to hemophilia, blood transfusion, or whose risk factor was not reported or not identified.
^f Data are based on residence at time of diagnosis of HIV infection.

Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas, 2019: Supplementary Tables

Download the Full Report pdf icon[PDF – 17 MB]

Report Contents

Other Reports